TLR3 and Middle East respiratory syndrome: In a vaccine candidate for Middle East respiratory syndrome (MERS), poly(I:C), a TLR3 adjuvant, was superior to alum when administered to mice with chimeric VLPs expressing MERS-CoV RBD protein by eliciting stronger neutralizing antibody as well as cell-mediated responses that prevented virus entry into susceptible cells [116].